2021 Virtual Global Policy Forum

Chaemin Shin Attendees Executive Director / Senior research fellow Neca(national Evidence-based Healthcare Collaborating Agency South Korea Organizational Member, HTAi Global Policy Forum Dr. Chaemin Shin is a senior research fellow and Executive Director of Division of New Health Technology Assessment at the National Evidence-based Healthcare Collaborating Agency (NECA). She has been working at NECA since 2010, and has conducted research mainly on policy approaches regarding the new health technology assessment program and policy emerging technologies. Since 2014, she had participated in Horizon Scanning Service Innovative Global Health Technology (H-SIGHT), the horizon scanning projects of NECA, and EuroScan International Network. Phone: +82-2-2174-2870 Email: [email protected] Aline Silveira Silva Technologist Brazilian Ministry of Health Brazil Invited Patient Representative Ph.D. in Sciences and Health Technology, research & practice in public and patient engagement since 2010. Oncological patient since 2013. Phone: +5561999439982 Email: [email protected] Twitter: @AlineSvSilva LinkedIn: linkedin.com/in/alinesilveirasilva Ann Single Coordinator Patient Voice Initiative Australia Invited Patient Representative Ann Single, B.Bus (Communication) MA (Writing), specialises in patient involvement and communication. She has been an active member of the HTAi Interest Group for Patient and Citizen Involvement in HTA for the past decade and became Chair in June 2019. Ann is a Steering Committee Member and Coordinator of the Patient Voice Initiative, is a lay reviewer for several journals and has previously worked as the director of communication and patient involvement in Scotland's HTA body, managed science engagement programmes in Australia, and served as secretary for a patient group. She is a co-editor of the book 'Patient Involvement in HTA' (June 2017) and has contributed to a variety of papers on patient involvement and tools for patient participation, including compiling a glossary of HTA terms for patients. Phone: +61434958390 Email: [email protected] Twitter: @asinglehaworth LinkedIn: linkedin.com/in/ann-single-95949619 99

Attendees Jean Slutsky Chief Engagement And Dissemination Officer Patient-Centered Outcomes Research Institute (PCORI) United States Organizational Member, HTAi Global Policy Forum Jean R. Slutsky is the Chief Engagement and Dissemination Officer at the Patient-Centered Outcomes Research Institute (PCORI). She leads PCORI’s Engagement Program and growing dissemination and implementation planning efforts. Before joining PCORI, Slutsky directed the Center for Outcomes and Evidence at the Agency for Healthcare Research and Quality, where she conceived and implemented the Effective Health Care program. The Effective Health Care program is an integrated program of research, stakeholder engagement, research training, and dissemination and implementation of comparative effectiveness research. Slutsky is particularly interested in pragmatic user-driven research and its implementation into healthcare decision making. Slutsky received her baccalaureate degree from the University of Iowa, trained as a Physician Assistant at the University of Southern California, and received a MSPH in health policy from the University of North Carolina at Chapel Hill. Phone: 202-744-4255 Email: [email protected] Maria Stewart Global Vice President, Health Economics and Market Access Boston Scientific Corporation United States Organizational Member, HTAi Global Policy Forum Maria has functional responsibility for developing and directing global strategies and methodologies for effective health economics and market access activities for Boston Scientific technologies. She and her cross-divisional team work closely with marketing, sales and clinical groups and collaborate with regional Health Economics and Market Access teams in Europe and Asia to support global technology assessments, coverage and funding for procedures using Boston Scientific’s products. Maria leads Boston Scientific’s efforts to shape Medicare coverage and payment policy and represents Boston Scientific in a number of industry and policy associations including AdvaMed, Health Technology Assessment International (HTAi), and the Duke Margolis Center for Health Policy. She also has direct responsibility for Boston Scientific’s Health Economics Center of Excellence and Payer Relations and Value-Based Offerings team, and she works closely with Boston Scientific’s Government Affairs and Global Health Policy organizations. In addition to her functional responsibilities, Maria is the Executive Sponsor of the Boston chapter of the Boston Scientific Women’s Network employee resource group. In this capacity, she fosters the professional development and advancement of female employees in support of diversity and inclusion at Boston Scientific. Maria has a BA in East Asian Studies from the University of Pennsylvania and an MA in Law and Diplomacy with concentrations in International Business and Technology Policy from the Fletcher School at Tufts University. Email: [email protected] Twitter: @mbstewart1265 LinkedIn: linkedin.com/in/maria-stewart-b196445 100

Racho Strauven Attendees Senior Director Health Economics and Market Access Boston Scientific Switzerland Organizational Member, HTAi Global Policy Forum Senior Director Health Economics and Market Access with over 15 years of experience in medical devices who has held key global and regional roles in Europe, US, Asia and Latin America. Email: [email protected] LinkedIn: linkedin.com/in/racho-strauven-6100a22 Rebecca Trowman Senior Manager Telethon Kids Institute Australia Scientific Secretary, HTAi Global Policy Forum Rebecca is the Scientific Secretary for the 2021 Global Policy Forum. She was previously the Director of Scientific Initiatives at HTAi. Rebecca has over 20 years of experience in the field of HTA. Her career began with formal training and conducting HTAs at the Centre for Reviews and Dissemination in York in the UK and she then worked in various technical capacities at NICE for nearly 10 years. After moving to Australia, Rebecca has been involved with the Department of Health in Western Australia, conducting state-based HTAs of medical devices, has initiated a disinvestment program and conducted workforce and service planning. She also established the Australian Clinical Trials: Impact & Quality (CT:IQ) initiative and is currently managing a research team at a research institute in Western Australia. Phone: 0451788259 Email: [email protected] Teresa Tseng International Health Policy, Sr Manager Amgen Inc United States Organizational Member, HTAi Global Policy Forum Dr. Teresa Tseng joined the International Health Policy team in 2019 at Amgen and is actively involved in strategic engagements and discussions around the challenge of access to combination therapy regimens. Prior to her role in health policy, Teresa supported the medical communication teams for 4 years. Teresa holds a Doctorate of Pharmacy for the University of Southern California, and a bachelor's degree in Biochemistry from University of California, Los Angeles. Email: [email protected] LinkedIn: linkedin.com/in/teresa-tseng-82408775 101

Attendees Sean Tunis HTAi Past President United States HTAi Past President Sean Tunis, MD, MSc. is a Principal with Rubix Health where he consults with public and private sector organizations on issues at the interface of regulatory and reimbursement policy, market access, comparative effectiveness, outcomes measurement and health technology assessment. Dr. Tunis is also the Founder and Senior Strategic Advisor with the Center for Medical Technology Policy in Baltimore, Maryland. CMTP is an independent, non-profit organization that provides a neutral platform for multi- stakeholder collaborations that are focused on improving the quality, relevance, and efficiency of clinical research. Dr. Tunis is the immediate past President of Health Technology Assessment International. Phone: +1 4109638876 Email: [email protected] Twitter: @CMTP_Baltimore, @SeanTunis Joice Valentim Health Systems Strategy Lead, HTA F. Hoffmann-La Roche Switzerland Organizational Member, HTAi Global Policy Forum Joice Valentim is Global Health Systems Strategy Lead for HTA, and prior Global Access Evidence Lead and Latin America HTA Policy Lead, at Roche Pharma. Joice is responsible for the Global HTA Strategy, leading the organization towards an unified HTA position to partner with stakeholders for early, holistic and deliberative HTA, locally appropriate and innovation-ready. Joice represents Roche at efpia, and before at the scientific committee of HTAi Policy Forum Latin America, ISPOR Industry Committee as past Latin America president, and FIFARMA. She was an invited professor at the University of São Paulo (MBA HTA, Health Economics/FIPE), a reviewer of scientific journals and author of articles and abstracts on HTA and HE. Prior to Roche, she worked at Novartis, and universities in Brazil as professor and researcher, including projects for the Ministry of Health (HTA project for the inclusion of new vaccines into the National Immunization Program/PNI) and the National Regulatory Agency for Private Health Insurance and Plans (ANS) of Brazil, PAHO, IDB and the World Bank. Economist, Joice holds a master degree in Economics and a doctorate degree in Preventive Medicine from the University of São Paulo. For more information please visit: http://buscatextual.cnpq.br/buscatextual/visualizacv.do?id=K4706373D5&idiomaExibicao=2\" Phone: +41795633832 Email: [email protected] LinkedIn: linkedin.com/in/joicevalentim-phd 102

Leonor Varela-Lema Attendees Senior Researcher Avalia-T (ACIS) Spain HTAi Board Director Since october 2020 she is professor in the Area of Preventive Medicine and Public Health, where she teaches in the Degree of Medicine, Nursery and in the Master of Public Health.She teaches and conducts acadamic research in relation to health care planning and management, public health programmes, among other subjects. Previously, she worked 18 years in the Galician Health Technology Assessment Agency (avalia-t) as international project manager, leading two activity centres in the ongoing European Network for Health Technology Assessment (EUnetHTA) JA3 EU-funded project (2016-2020). She is still acting as an advisor for avalia-t in internal affairs. She is also member of the expert panel on medical devices of the European Comission (EXPAMED). Phone: +34881548609 Email: [email protected] Rosa Maria Vivanco-Hidalgo Head Of Health Technology Assessment Area AQuAS Spain Organizational Member, HTAi Global Policy Forum Rosa Maria Vivanco-Hidalgo (F) MD, PhD (Autonomous University of Barcelona), MPH (Pompeu Fabra University, Barcelona). Specialist in Neurology. Master in Public Health and Degree on Biostatistics. She is a senior research of AQuAS and the current Director of the Health Technology Assessment Unit. Other areas of interest and experience are observational studies in clinical practice and health services, use of RWD to generate RWE. She has worked in commissioned projects for the Catalan Health Ministries and international research projects (currently: scientific leader of Interreg SUDOE ICTUSnet project, which aims to improve the quality of stroke healthcare, by promoting collaboration in R&D, fostering mutual learning and promoting innovation in stroke care strategies in the Southwest regions of EU through the incorporation of new technologies for big data analysis). She has published scientific papers and HTA reports using mainly quantitative methodology. Email: [email protected] Twitter: @vivanco_hidalgo 103

Attendees Franz Waibel Senior Advisor & Consultant Self-employed Switzerland HTAi Board Director Dr. Franz Waibel serves as HTAi Board Director since July 2020. He is a member of HTAi since 2005 and has engaged in the Global Policy Forum and the Patient and Citizen Involvement Interest Group (PCIG). He has over 30 years of experience in the field of value assessment of medicines and medical products and has been involved in HTA matters throughout his career. He worked for over 25 years in leading BioPharma companies at locations in Europe and the US and in global leadership roles in the fields of patient access, public affairs and policy. Since 2014, he provides services as an independent strategic advisor and consultant on strategic healthcare matters. He also engages in investment and innovation promotion for the Basel Area, Switzerland, where he resides with his family. He is passionate about strengthening patient involvement in HTA and Healthcare, keen to further multi- stakeholder dialogue and engages in healthcare system and HTA policy matters across many jurisdictions worldwide. Franz Waibel holds a PhD in Cell Biology from Basel University, Switzerland, an MBA from Birmingham University, UK and a BS from Freiburg University, Germany. He holds Swiss and German citizenships. Phone: +41795454458 Email: [email protected] Twitter: @FranzWaibel LinkedIn: linkedin.com/in/franzwaibel Martin Walter Global Head of Market Access Boehringer Ingelheim International Gmbh Germany Organizational Member, HTAi Global Policy Forum Martin Walter is Global Head of Market Access for Boehringer Ingelheim’s Human Pharma business. Before that he has held various pricing and market access roles with increasing responsibilities across Boehringer’s primary care, specialty care and biosimilar portfolio. Prior to joining BI Martin has spent several years in lifescience consulting, where he supported major global pharmaceutical, biotech and medtech companies, in Europe, the US, Asia and emerging markets on marketing and market access questions. Over the last 15 years Martin has built a track record of delivering strategic priorities in lifesciences, most notably addressing pricing & market access yield, growth & commercial strategy. Martin holds a Ph.D. in theoretical physics and lives in Germany with his wife and two sons. Email: [email protected] 104

Tina Wang Attendees HTA Programme Manager Centre for Innovation in Regulatory Science United Kingdom Invited Speaker Tina Wang is the Manager of the HTA programme at the Centre for Innovation in Regulatory Science ( At CIRS, Tina's scope of responsibilities covers all aspect of a programme through conception to delivery. These include developing programme strategy, managing clients communications, co-organizing multi- stakeholder workshops, coordinating an HTA steering committee, and managing various HTA projects and product. Tina received her undergraduate degree in Applied Chemistry from the Beijing University of Technology and a Master of Science in Pharmaceutical Analysis and Quality Control from Kings College, University of London Ms Wang is pursuing the PhD at the WHO Collaborating Centre for Pharmaceutical Policy and Regulation, Utrecht University, her research focused on “Ensuring equitable access to new medicine through quality decision making”. Prior to joining CIRS in 2010, Ms Wang worked as a research scientist at Medpharm and GlaxoSmithKline. Ms Wang’s main field of interest is the international HTA policy and intelligence. Phone: +44 207 433 4165 Email: [email protected] Andrew Wilson Chair Pharmaceutical Benefits Advisory Committee, Australian Dept of Health Australia Organizational Member, HTAi Global Policy Forum Professor Andrew Wilson is the Chair of the Australian Government Pharmaceutical Benefits Advisory Committee. He is the Co-Director of the Menzies Centre for Health Policy at the University of Sydney and Co-Director of the NHMRC Prevention Partnership Centre based at the Sax Institute. Email: [email protected] 105

INNOVATION THROUGH HTA HTAi invites you to join the leading minds in Health Technology Assessment (HTA) from around the world to discuss and debate the role of HTA in leading health innovation in this year's virtual Annual Meeting. The 2021 Annual Meeting will focus on how adaptive approaches to HTA can continue to provide the cornerstone in leading health systems innovation. As our technological world evolves and new challenges emerge, we will need to adapt HTA to ensure it continues to be a conduit to support technology innovation. JUNE 19 – 23, 2021

WANT TO GET MORE INVOLVED IN A WORKING GROUP OR PROJECT? Join an HTAi Interest Group! Did you know: • HTAi has 10 different Interest Groups • 60% of HTAi members belong to one or more Interest Group • Fosters project collaboration, facilitates the exchange of information, and sets the stage for networking on small-scale initiatives through to engagement in larger, multi-stakeholder international projects Involvement in the IGs is open to all HTAi members with current membership, allowing you to keep up with IG activities and opportunities to get more involved in specific working groups and projects. Want more info? Visit https://htai.org/interest-groups

2022 GLOBAL POLICY FORUM The Hague, Netherlands January 23-26, 2022

1200, 10405 Jasper Avenue, Edmonton, Alberta, Canada T5J 3N4 Tel: 780.448.4881 Fax: 780.448.0018 E-mail: [email protected] Twitter: twitter.com/HTAiOrg Facebook: facebook.com/HTAiOrg LinkedIn: linkedin.com/company/htai www.HTAi.org